Search
for

    GlossaryManagement Strategies

    planned methods to address and mitigate specific issues or conditions

    Management Strategies refer to the planned methods or approaches used to address and mitigate a specific issue or condition. In the context of hair and alopecia, these strategies might include medical treatments like topical minoxidil, lifestyle changes such as stress management, and cosmetic solutions like wigs or hairpieces. These strategies aim to either slow down hair loss, promote hair regrowth, or manage the psychological impact of the condition.

    Related Terms

    Learn

    5 / 801 results

    Research

    5 / 1000+ results

    Community Join

    5 / 151 results

      community An updated, simple guide to the most effective hair loss treatments

       193 upvotes 6 years ago
      Effective treatments for hair loss, including Dutasteride, Finasteride, Minoxidil, Dermarolling, LLLT, PRP, Ketoconazole, and Scalp Massage. In addition, anti-inflammatory diets and stress management are recommended to maintain or regrow hair.

      community (Europe) looking for advice on topical anti androgen use

      in Treatment  3 upvotes 7 months ago
      The user is using finasteride, minoxidil, and ciclopirox shampoo for hair loss and is considering adding a topical anti-androgen like RU58841, Clacosterone, or KX286. They have scheduled a hair transplant and are concerned about the cost and effectiveness of future treatments.

      community He used Dutasteride for 20 years. Interview

      in Treatment  114 upvotes 1 year ago
      Dutasteride has been used for 20 years with some hair thickness improvement but no dramatic regrowth. The user also experimented with minoxidil, tretinoin, and peptides like BPC 157 for potential benefits in hair density and quality.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 3 years ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.